SGMO
Sangamo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.07
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 34.6M | 39.6M | 57.8M | 176.2M | 111.3M |
| Cost of Revenue | — | 7.6M | — | — | 12.1M |
| Gross Profit | 34.6M | 31.9M | 57.8M | 176.2M | 99.2M |
| Operating Expenses | |||||
| R&D Expense | 113.2M | 112.7M | 111.5M | 234.1M | 249.9M |
| SG&A Expense | 31.6M | 34.9M | 44.7M | 61.2M | 62.7M |
| General & Admin Expense | 31.6M | 34.9M | 44.7M | 61.2M | 62.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (7.6M) | 5.5M | 155.0M | (12.1M) |
| Total Operating Expenses | 144.9M | 140.0M | 161.8M | 450.2M | 300.5M |
| Cost and Expenses | 144.9M | 147.6M | 161.8M | 450.2M | 312.6M |
| Operating Income (EBIT) | (110.3M) | (108.0M) | (104.0M) | (274.0M) | (201.3M) |
| Non-Operating | |||||
| Interest Income | 1.3M | 1.3M | 5.9M | 11.1M | 9.4M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 1.3M | 1.3M | 5.9M | 11.1M | 9.4M |
| Other Non-Op Income/Expense | (13.7M) | (15.5M) | 5.9M | 11.1M | 9.4M |
| Non-Operating Income (excl Interest) | 13.7M | 15.5M | (5.5M) | (155.0M) | (9.4M) |
| EBT (Pre-Tax Income) | (124.0M) | (123.5M) | (98.1M) | (262.9M) | (191.8M) |
| Income Tax Expense | (687.0K) | (568.0K) | (167.0K) | (5.1M) | 429.0K |
| Bottom Line | |||||
| Net Income | (123.3M) | (122.9M) | (97.9M) | (257.8M) | (192.3M) |
| Earnings from Cont. Ops | (123.3M) | (122.9M) | (97.9M) | (257.8M) | (192.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (123.3M) | (122.9M) | (97.9M) | (257.8M) | (192.3M) |
| Per Share | |||||
| Basic EPS | ($0.38) | ($0.44) | ($0.49) | ($1.48) | ($1.25) |
| Diluted EPS | ($0.38) | ($0.44) | ($0.49) | ($1.48) | ($1.25) |
| Revenue Per Share | $0.09 | $0.14 | $0.29 | $1.01 | $0.72 |
| Shares | |||||
| Basic Shares Outstanding | 389.6M | 280.2M | 201.7M | 174.4M | 154.3M |
| Diluted Shares Outstanding | 389.6M | 280.2M | 201.7M | 174.4M | 154.3M |
| Profitability Metrics | |||||
| EBITDA | (117.5M) | (115.9M) | (89.1M) | (96.8M) | (179.7M) |
| D&A | 6.6M | 7.6M | 9.4M | 22.2M | 12.1M |
| EBIT | (124.0M) | (123.5M) | (98.4M) | (119.0M) | (191.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026